Vaccine Therapy For Colon Cancer.

Publication/Presentation Date

1999

Abstract

Conclusions A meta-analysis of all three trials with 723 patients has been concluded, and is currently being submitted for publication. Our conclusions at this point are that the data are sufficiently compelling to suggest that active specific immunotherapy with an autologous tumor cell plus BCG vaccine should be considered as a standard therapy for patients with stage II colon cancer. A phase III trial in Stage III colon cancer comparing surgical resection followed by six months of 5-FU/leucovorin chemotherapy followed by a fourth vaccine boost at 6 months versus surgical resection alone, is being started in Europe and the United States.

Volume

2

Issue

5

First Page

343

Last Page

348

Disciplines

Medicine and Health Sciences | Other Medical Specialties | Surgery

Department(s)

Department of Surgery, Department of Surgery Faculty

Document Type

Article

Share

COinS